

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

Contribution Agreement

CONVEYING PARTY DATA

Name	Execution Date
ICN Pharmaceuticals, Inc.	08/20/2002

RECEIVING PARTY DATA

Name:	Ribapharm Inc.
Street Address:	3300 Hyland Avenue
City:	Costa Mesa
State/Country:	CALIFORNIA
Postal Code:	92626

PROPERTY NUMBERS Total: 9

Property Type	Number
Patent Number:	5990299
Patent Number:	5723589
Patent Number:	6403566
Patent Number:	6083482
Patent Number:	6518253
Patent Number:	5681940
Patent Number:	5712378
Patent Number:	5969135
Patent Number:	5932556

CORRESPONDENCE DATA

Fax Number: (212)895-2900

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-895-2000

Email: jpassner@brownraysman.com

Correspondent Name: Brown Raysman Millstein Felder & Steiner

Address Line 1: 900 Third Avenue

PATENT

500024962

REEL: 015819 FRAME: 0595

CH \$360.00 5990299

Address Line 4: New York, NEW YORK 10022

NAME OF SUBMITTER:

James P. Demers

Total Attachments: 41

source=Contribution Agreement (complete)#page1.tif
source=Contribution Agreement (complete)#page2.tif
source=Contribution Agreement (complete)#page3.tif
source=Contribution Agreement (complete)#page4.tif
source=Contribution Agreement (complete)#page5.tif
source=Contribution Agreement (complete)#page6.tif
source=Contribution Agreement (complete)#page7.tif
source=Contribution Agreement (complete)#page8.tif
source=Contribution Agreement (complete)#page9.tif
source=Contribution Agreement (complete)#page10.tif
source=Contribution Agreement (complete)#page11.tif
source=Contribution Agreement (complete)#page12.tif
source=Contribution Agreement (complete)#page13.tif
source=Contribution Agreement (complete)#page14.tif
source=Contribution Agreement (complete)#page15.tif
source=Contribution Agreement (complete)#page16.tif
source=Contribution Agreement (complete)#page17.tif
source=Contribution Agreement (complete)#page18.tif
source=Contribution Agreement (complete)#page19.tif
source=Contribution Agreement (complete)#page20.tif
source=Contribution Agreement (complete)#page21.tif
source=Contribution Agreement (complete)#page22.tif
source=Contribution Agreement (complete)#page23.tif
source=Contribution Agreement (complete)#page24.tif
source=Contribution Agreement (complete)#page25.tif
source=Contribution Agreement (complete)#page26.tif
source=Contribution Agreement (complete)#page27.tif
source=Contribution Agreement (complete)#page28.tif
source=Contribution Agreement (complete)#page29.tif
source=Contribution Agreement (complete)#page30.tif
source=Contribution Agreement (complete)#page31.tif
source=Contribution Agreement (complete)#page32.tif
source=Contribution Agreement (complete)#page33.tif
source=Contribution Agreement (complete)#page34.tif
source=Contribution Agreement (complete)#page35.tif
source=Contribution Agreement (complete)#page36.tif
source=Contribution Agreement (complete)#page37.tif
source=Contribution Agreement (complete)#page38.tif
source=Contribution Agreement (complete)#page39.tif
source=Contribution Agreement (complete)#page40.tif
source=Contribution Agreement (complete)#page41.tif

CONTRIBUTION AGREEMENT

This Contribution Agreement (the "Agreement") is made and entered into as of August 20, 2002 between ICN Pharmaceuticals, Inc., a Delaware corporation ("ICN") and Ribapharm Inc., a Delaware corporation ("Ribapharm").

WHEREAS, pursuant to duly adopted resolutions of the board of directors of ICN dated August 7, 2000 (the "August 2000 Resolutions") attached hereto as Schedule A, ICN contributed all of its right, title and interest in the Contributed Assets (as defined in the August 2000 Resolutions) including, without limitation, ICN's rights under the License and Supply Agreement by and between ICN and Schering-Plough Ltd. ("Schering") dated July 28, 1995 (the "S-P License");

WHEREAS, pursuant to duly adopted resolutions of the board of directors of ICN dated February 7, 2002 (the "February 2002 Resolutions") attached hereto as Schedule B, ICN (i) rescinded the contribution of the Costa Mesa Facility (as defined in the August 2000 Resolutions), (ii) contributed all of ICN's rights, title and interest in Hepavir B to Ribapharm and (iii) contributed all of ICN's rights, title and interest in IL-12 to Ribapharm;

WHEREAS, ICN, Schering and Ribapharm entered into a letter agreement dated March 8, 2002 (the "Consent") further outlining the rights and obligations of ICN, Schering and Ribapharm under the S-P License; and

WHEREAS, to facilitate the orderly recordation of transfer with the appropriate agencies, ICN and Ribapharm desire to set out with particularity a list of patents, trademarks, patent applications, trademark applications and any continuation, division, renewal, substitute, reissue or reexamination thereof contributed pursuant to the August 2000 Resolutions and February 2002 Resolutions (which list shall not be deemed to be a complete list of all patents and trademarks contributed by the August 2002 Resolutions and February 2002 Resolutions).

NOW, THEREFORE, the parties agree as follows:

1. ICN reaffirms (a) the contribution of Contributed Assets, except the Costa Mesa Facility contribution rescinded by the February 2002 Resolutions and (b) the contribution of Hepavir B and IL-12 made by the February 2002 Resolutions.

2. Ribapharm reaffirms its acceptance of (a) the contribution of Contributed Assets, except the Costa Mesa Facility contribution rescinded by the February 2002 Resolutions and (b) the contribution of Hepavir B and IL-12 made by the February 2002 Resolutions.

3. ICN and Ribapharm agree that the Contributed Assets include, without limitation, the patents, trademarks, patent applications, and any continuation, division, renewal, substitute, reissue or reexamination thereof set forth on Schedule C.

IN WITNESS WHEREOF, the undersigned have caused their duly authorized officers to execute this Agreement on the date first above written.

ICN PHARMACEUTICALS, INC.

By: _____

Name: Harry A. Roosje

Title: Senior Vice President and Associate
General Counsel

RIBAPHARM INC.

By: _____


Name: Roger D. Loomis, Jr.

Title: Senior Vice President and
General Counsel

State of California
County of Orange

Subscribed and sworn to before me this 20th day of August, 2002
by Roger D. Loomis, Jr. and Harry A. Roosje

Caroline S. Fauske
Notary Public



SCHEDULE A

August 7, 2000

CERTIFICATE OF OFFICER

I, David C. Watt, a duly elected and qualified Officer of ICN Pharmaceuticals, Inc., a Delaware corporation (the "Company"), in accordance with applicable provisions of the Delaware General Corporation Law, hereby certify that the Board of Directors of the Company adopted the following resolutions at a meeting of the Board of Directors of the Company held on August 7, 2000, and that such resolutions have not been revoked and remain in full force and effect as of the date hereof.

WHEREAS, this Corporation caused Ribapharm Inc. ("Ribapharm") to be incorporated on April 14, 2000 and purchased 100 shares of the common stock of Ribapharm on May 1, 2000; and

WHEREAS, Ribapharm is a wholly-owned subsidiary of this Corporation; and

WHEREAS, this Board has determined that this Corporation should conduct all of its research and development activities in the United States (the "U.S. R&D Activities") through Ribapharm; and

WHEREAS, to accomplish this objective, this Corporation has decided to contribute to Ribapharm all of its assets related to the U.S. R&D Activities, as well as its rights under the License and Supply Agreement by and between ICN Pharmaceuticals, Inc. and Schering-Plough Ltd., dated July 28, 1995, as amended (the "S-P License Agreement") and related agreements, in each case subject to the qualifications set forth below (collectively, the "Contributed Assets"); and

WHEREAS, Ribapharm has received comments from the Securities and Exchange Commission (the "SEC") on its Registration Statement on Form S-1 (Registration No. 333-39350) with respect to the initial public offering of common stock of Ribapharm IPO (the "Ribapharm IPO") and it is advisable that this Corporation cause Ribapharm to file an amendment to its Registration Statement on Form S-1 in response to such comments and reflecting additional changes to the proposed structure of the Ribapharm IPO; and

WHEREAS, this Corporation has determined that in connection with the Ribapharm IPO, it is in the best interests of this Corporation to make an offer to purchase all of its outstanding 8 ¾% Senior Notes due 2008 (the "8 ¾% Senior Notes") and 9 ¾% Senior Notes (together with the 8 ¾% Senior Notes, the "Senior Notes") and to amend certain provisions of the indentures under which the Senior Notes were issued (the "Debt Offer and Consent"); and

WHEREAS, this Corporation has determined that it is desirable to seek bank or other financing to obtain the funds necessary to consummate the Debt Offer and Consent;

ffny03\lanange\365936.1

NOW, THEREFORE, BE IT RESOLVED that this Corporation hereby contributes to Ribapharm all of its rights, title and interest in the Contributed Assets, including, without limitation, the following:

- (i) all chemical compounds related to the U.S. R&D Activities, including, without limitation, ribavirin (but excluding the Approved Indications for Ribavirin (as defined below), which are hereby being retained by this Corporation on a perpetual exclusive royalty-free basis), Levovirin, Viramidine, Tiazole (tiazofurin), Adenazole (8-Cl cAMP, Tocladesine), and all other nucleoside analog compounds, along with all related patents and patent applications, trademarks and trademark applications, goodwill, trade secrets, records, journals, data, equipment, materials and supplies (including, without limitation, the patents, trademarks, patent applications and trademark applications listed on Exhibit A and the goodwill related thereto, but excluding, without limitation, the patents, trademarks, patent applications and trademark applications listed on Exhibit B and the goodwill related thereto);
- (ii) the real property located at 3300 Hyland Avenue, Costa Mesa, CA 92626, including all buildings, fixtures in such buildings, and structures and other improvements situated thereon (the "Costa Mesa Facility");
- (iii) all furniture, equipment, materials, supplies, data, journals and records located at the Costa Mesa Facility and related to, or used in connection with, the U.S. R&D Activities (except for those assets listed on Exhibit C);
- (iv) the S-P License Agreement; and
- (v) all contracts between this Corporation and third parties relating to the U.S. R&D Activities or the S-P License Agreement, other than any contracts relating to the Approved Indications for Ribavirin;

provided, however, that to the extent the contribution of any asset hereunder requires the approval of the Office of Foreign Assets Control of the U.S. Department of the Treasury, such contribution shall not be effective unless and until such approval shall have been obtained;

provided, further, that the contribution of the S-P License Agreement and all contracts related thereto shall not be effective unless and until all requisite consents to the contribution of the S-P License Agreement and all such related contracts under the terms of the indentures relating to the Senior Notes have been obtained or are no longer required.

RESOLVED FURTHER, that, as used in the foregoing resolution, the term "Approved Indications for Ribavirin" shall mean all indications for ribavirin in a given jurisdiction to the

extent currently approved in that jurisdiction (but not in other jurisdictions for which that indication is not currently approved) as well as the potential indication for use of ribavirin in aerosol form in connection with treating RSV infections in bone marrow transplant patients (provided that the term "Approved Indications for Ribavirin" shall not include the use of ribavirin for the treatment of Hepatitis C (regardless of method of delivery)).

RESOLVED FURTHER, that the officers of this Corporation be, and each of them hereby is, authorized and empowered to cause Ribapharm to file with the SEC an amendment to its Registration Statement on Form S-1 substantially in the form presented to the directors for their consideration at this Board of Directors meeting, with any and all modifications or changes any such officer may deem necessary, desirable or advisable to be made consistent with the discussions that took place at this Board of Directors meeting.

RESOLVED FURTHER, that the officers of this Corporation be, and each of them hereby is, authorized, on behalf of this Corporation, to negotiate the terms of the Debt Offer and Consent and the terms of the bank or other debt financing necessary to finance the Debt Offer and Consent (the "Debt Refinancing"), subject to final approval of the terms of the Debt Offer and Consent and the Debt Refinancing by the Board of Directors.

RESOLVED FURTHER, that, in connection with the Debt Offer and Consent, the officers of this Corporation be, and each of them hereby is, authorized, in the name and on behalf of this Corporation, to hire such advisers and agents, including without limitation dealer managers, depositaries, information agents and lawyers as any such officer may deem necessary or desirable, such hiring conclusively to evidence the due authorization thereof by this Corporation.

RESOLVED FURTHER, that the officers of this Corporation are authorized on behalf of this Corporation to enter into any agreements or execute any instruments useful or necessary to effect the intent of the foregoing resolutions.

WITNESS my hand this 8th day of April, 2002.



David C. Watt

Executive Vice President

Matters Moved to Subsidiary

Topic	Matter ID	Title	Matter Type	Status	Expiration Date	Patent Number
Ribavirin	109/097-EP2	Ribavirin Human Use	Patent - Foreign	Pending		
Ribavirin	109/097-Germany	Ribavirin (Human Antiviral use)	Patent - Foreign	Pending		
Ribavirin	109/097-Hong Kong	Ribavirin Human Use	Patent - Foreign	Issued	08/05/05	2005448
Ribavirin	109/097-Japan	Ribavirin Human Use	Patent - Foreign	Issued	08/27/12	1330073
Adenazole	182/262-Canada (D1)	8-Chloroadenazole 3',5'-Cyclic monophosphate Preparations	Patent - Foreign	Issued	12/21/07	549670
Tiazofurin	184/002-Australia	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-Austria	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-Belgium	Tiazofurin	Patent - Foreign	Issued	10/02/01	1175421
Tiazofurin	184/002-Canada-D1	Tiazofurin	Patent - Foreign	Issued	12/14/01	76573
Tiazofurin	184/002-Finland	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-France	Tiazofurin	Patent - Foreign	Issued	12/14/01	p3177155.6-80
Tiazofurin	184/002-Germany	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-Great Britain	Tiazofurin	Patent - Foreign	Issued	12/14/01	54536
Tiazofurin	184/002-Israel	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-Italy	Tiazofurin	Patent - Foreign	Issued	07/02/02	1775305
Tiazofurin	184/002-Japan	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-Luxembourg	Tiazofurin	Patent - Foreign	Issued	12/14/01	54432
Tiazofurin	184/002-Netherlands	Tiazofurin	Patent - Foreign	Issued	12/14/01	190285
Tiazofurin	184/002-New Zealand	Tiazofurin	Patent - Foreign	Issued	12/14/01	150242
Tiazofurin	184/002-Norway	Tiazofurin	Patent - Foreign	Issued	12/10/01	81/8591
Tiazofurin	184/002-S. Africa	Tiazofurin	Patent - Foreign	Issued	11/30/09	247218
Sulfazine	185/103-Argentina	Sulfazine	Patent - Foreign	Issued	12/13/08	E 109791
Sulfazine	185/103-Austria	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-Belgium	Sulfazine	Patent - Foreign	Issued	05/04/10	1317291
Sulfazine	185/103-Canada	Sulfazine	Patent - Foreign	Issued	12/13/08	353268
Sulfazine	185/103-France	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-G. Britain	Sulfazine	Patent - Foreign	Issued	12/13/08	P3851054.5-08
Sulfazine	185/103-Germany	Sulfazine	Patent - Foreign	Issued	12/13/08	100386
Sulfazine	185/103-Greece	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-Italy	Sulfazine	Patent - Foreign	Issued	12/13/05	500646/89
Sulfazine	185/103-Japan	Sulfazine	Patent - Foreign	Issued	02/11/13	137763
Sulfazine	185/103-Korea (S)	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-Luxembourg	Sulfazine	Patent - Foreign	Issued	12/08/08	177733
Sulfazine	185/103-Mexico	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-Netherlands	Sulfazine	Patent - Foreign	Issued	12/13/08	not found
Sulfazine	185/103-New Zealand	Sulfazine	Patent - Foreign	Issued	12/13/08	not found

1/26/01

1 of 11

ICN Patents Schedules-02d (as of Aug 7, 2000).xls

PATENT
REEL: 015819 FRAME: 0602

ICN D1:1 N 26:85

11-27-1-10-0044

Exhibit A

NOV 02 '01 12:38

71463591.36

PAGE: 85

Matters Moved to Subsidiary

Sulfazine	185/103-Spain	Sulfazine	Patent - Foreign	Issued	not found	2013379
Sulfazine	185/103-Sweden	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-Switzerland	Sulfazine	Patent - Foreign	Issued	12/13/08	353 268
Sulfazine	185/103-US	Sulfazine	Patent - US	Issued	08/20/08	5041542
Adenazole	195/183 - (ICH) US5	Adenazole (8-Cl-cAMP)	Patent - US	Issued	05/10/15	5783419
Adenazole	195/183 - (NIT) US3	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/11/15	5782752
Adenazole	195/183 - (NIT) US4	Adenazole (8-Cl-cAMP)	Patent - US	Issued	05/01/12	5843616
Adenazole	195/183 - (NIT) US5	Adenazole (8-Cl-cAMP)	Patent - US	Issued	05/23/08	5902794
Ribavirin	198/298-US	Virazole Derivative	Patent - US	Issued	11/02/08	4825630
PyridylPyrimidines	198/297-US	Substituted Pyrimido [5,4-D] Pyrimidine . . .	Patent - US	Issued	06/03/08	5041542
Sulfazine	198/298-US1	Sulfenamide, Sulfenamide and Sulfonamide Purines and Processes of	Patent - US	Issued	11/22/08	5026838
Tiazofurin	198/300-US	Treatment of malignant Tumors with 2-(8-D-Ribofuranosylthiazole-4-C	Patent - US	Issued	02/27/05	4680285
Adenazole	198/302-US	8-Chloroadenine 3',5'-Cyclic Monophosphate Preparations	Patent - US	Issued	12/11/07	4861873
Oncozole	201/068-Belgium	Oncozole	Patent - Foreign	Issued	08/15/03	103417
Oncozole	201/068-Canada	Oncozole	Patent - Foreign	Issued	08/27/06	1254568
Oncozole	201/068-Denmark	Oncozole	Patent - Foreign	Issued	02/14/04	158001
Oncozole	201/068-France	Oncozole	Patent - Foreign	Issued	08/15/03	103417
Oncozole	201/068-Germany	Oncozole	Patent - Foreign	Issued	08/16/03	103417
Oncozole	201/068-Ireland	Oncozole	Patent - Foreign	Issued	07/27/03	55646
Oncozole	201/068-Italy	Oncozole	Patent - Foreign	Issued	08/15/03	103417
Oncozole	201/068-Japan	Oncozole	Patent - Foreign	Issued	08/16/03	103417
Oncozole	201/068-Luxembourg	Oncozole	Patent - Foreign	Issued	08/17/03	103417
Oncozole	201/068-Netherlands	Oncozole	Patent - Foreign	Issued	08/18/03	103417
Oncozole	201/068-Spain	Oncozole	Patent - Foreign	Issued	10/23/04	5250102
Oncozole	201/068-Sweden	Oncozole	Patent - Foreign	Issued	08/18/03	103417
Oncozole	201/068-Switzerland	Oncozole	Patent - Foreign	Issued	08/18/03	103417
Oncozole	201/068-US	Oncozole	Patent - US	Issued	01/21/06	4761478
Oncozole	201/068-Portugal-1	Oncozole	Patent - Foreign	Issued	02/04/06	76426
Selenazole	201/092-Denmark	Selenazole compounds and method for production	Patent - Foreign	Issued	03/22/03	25093
Tiazofurin	201/223-Argentina	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201/223-Australia	Tiazofurin & Ribavirin	Patent - Foreign	Issued	05/14/14	878531
Tiazofurin	201/223-Brazil	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201/223-EPO	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201/223-Hong Kong	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201/223-Japan	Tiazofurin & Ribavirin	Patent - Foreign	Issued	09/03/00	2851407
Tiazofurin	201/223-Korea (S)	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201/223-Mexico	Tiazofurin & Ribavirin	Patent - Foreign	Pending		

Matters Moved to Subsidiary

Tiazofurin	201/223-New Zealand	Tiazofurin & Ribavirin	Patent - Foreign	Issued	11/03/14	286358
Tiazofurin	201/223-Russian Fed	Tiazofurin & Ribavirin	Patent - Foreign	Pending		
Tiazofurin	201/223-US	Tiazofurin & Ribavirin	Patent - US	Issued	05/18/13	5405837
Selenazole	208/165-US	Selenazole	Patent - US	Issued	06/22/04	4594414
Selenazole	208/166-US1	Selenazole	Patent - US	Issued	07/23/04	4594416
Selenazole	207/075-US	Selenazole	Patent - US	Issued	07/09/04	4619988
Sugar Mod Nucle	213/001-Australia	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	11/02/15	690384
Sugar Mod Nucle	213/001-Canada	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Allowed		
Sugar Mod Nucle	213/001-China	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Czech	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-EPO	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Hong Kong	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Hungary	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Japan	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Korea (S)	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Mexico	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Poland	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Russian Fed	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Slovakia	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending		
Sugar Mod Nucle	213/001-Ukraine	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	11/02/14	5681940
Sugar Mod Nucle	213/001-US1	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	11/02/14	5712378
Sugar Mod Nucle	213/001-US2	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Pending		
Sugar Mod Nucle	213/001-US3	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	06/23/16	8520113
Sugar Mod Nucle	213/001-Yugoslavia (S)	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	11/02/15	693622
AANA	213/002-Australia	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Canada	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-China	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Czech	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-EPO	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-foreign gen	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Hungary	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Japan	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Korea (S)	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Mexico	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Poland	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Russian Fed	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AANA	213/002-Slovakia	Amino Acid Nucleic Acids	Patent - Foreign	Pending		

Matters Moved to Subsidiary

AAHA	213/002-Ukraine	Amino Acid Nucleic Acids	Patent - Foreign	Pending		
AAHA	213/002-US	Amino Acid Nucleic Acids	Patent - US	Issued	11/02/15	5688135
AAHA	213/002-Yugoslavia	Amino Acid Nucleic Acids	Patent - Foreign	Issued	04/29/17	9528112
CD28 18064	213/003-Australia	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	02/15/16	703139
CD28 18064	213/003-Canada	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-China	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-Czech	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-EPO	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-Hungary	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-Japan	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	08/09/17	258826
CD28 18064	213/003-Korea (S)	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	218/000-Mexico	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/000-Poland	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-Russian Fed	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-Slovakia	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Pending		
CD28 18064	213/003-Ukraine	Methods and Compositions for Regulation of CD28 Expression	Patent - US	Issued	08/18/15	5932568
CD28 18064	213/003-US2	Methods and Compositions for Regulation of CD28 Expression	Patent - US	Issued	11/16/16	706006
IL8 Antisense	213/015-Australia	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Bosnia&Herz	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Canada	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-China	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Czech	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-EPO	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Hong Kong	Inhibition of Tumor Growth by Antisense Oligonucleotides for ...	Patent - Foreign	Pending		
IL8 Antisense	213/015-Hungary	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Japan	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Korea (S)	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Macedonia	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Mexico	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Poland	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Russian Fed	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Slovak	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	05/03/18	19620122
IL8 Antisense	213/015-Slovenia	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Pending		
IL8 Antisense	213/015-Ukraine	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - US	Issued	11/21/15	5849903
IL8 Antisense	213/015-US2	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - US	Issued	02/05/17	8017808
IL8 Antisense	213/015-US4	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	07/31/06	704579
CD44 Antisense	213/027-Australia	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Issued		

Matters Moved to Subsidiary

CD44 Antisense	213/027-Canada	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-China	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Czech	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-EPO	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Hong Kong	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Hungary	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Israel	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Japan	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Korea (S)	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Mexico	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Poland	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Russian Fed	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Slovak	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Ukraine	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Issued	08/14/15 5000290
CD44 Antisense	213/027-US2	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Pending	
CD44 Antisense	213/027-US3	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Yugoslavia(M	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
CD44 Antisense	213/027-Yugoslavia(S	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Pending	
Ginkgolides	213/028-Australia	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Canada	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-China	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Czech	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-EPO	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Pending	
Ginkgolides	213/028-foreign gener	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Hungary	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Japan	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Korea (S)	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Mexico	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Poland	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Issued	12/12/16 RU 2141083
Ginkgolides	213/028-Russian	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Slovak	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	
Ginkgolides	213/028-Ukraine	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Issued	12/21/15 5723580
Ginkgolides	213/028-US1	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Issued	01/21/17 700642
Ribavirin	213/102-Australia	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Ribavirin	213/102-Bosnia	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	
Ribavirin	213/102-Brazil	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	01/21/17 2246162
Ribavirin	213/102-Canada	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	

Matters Moved to Subsidiary

Ribavirin	213/102-China	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Czech	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-EPO	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Hong Kong	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Hungary	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Israel	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Japan	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Korea	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Mexico	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-New Zealand	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed		
Ribavirin	213/102-Norway	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Poland	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Russian Fed.	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Slovakia	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Ukraine	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-US1	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	01/23/16	5767097
Ribavirin	213/102-US2	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	01/23/16	6063772
Ribavirin	213/102-US3	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Allowed		
Ribavirin	213/102-Yugo (Maced)	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending		
Ribavirin	213/102-Yugo (Slovak)	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	07/20/18	9720013
Tiazofurin	213/133-US1	Manufacturing L-Ribo-C-nucleosides	Patent - US	Issued	05/25/99	5907036
Purine-L-Nucleoside	216/009-Argentina	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Australia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Bosnia&Hers	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Brazil	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Canada	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-China	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Croatia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Czech	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-EPO	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Hong Kong	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Hungary	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-India	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Israel	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Japan	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Korea	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		
Purine-L-Nucleoside	216/009-Macedonia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		

Matters Moved to Subsidiary

Purine-L-Nucleoside	216/009-Mexico	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-New Zealand	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/009-Norway	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/008-Poland	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/009-Russia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/009-Serbia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/009-Slovenia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	10/15/17 20024
Purine-L-Nucleoside	216/008-Slovenia	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/009-Ukraine	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Purine-L-Nucleoside	216/009-US2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending	
Levovirin 17261	216/010-Argentina	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Australia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Bosnia&Hers	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Brazil	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Canada	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-China	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Croatia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Czech	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-EPO	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Hungary	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-India	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Israel	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Japan	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Korea	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Macedonia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Mexico	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-New Zealand	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Norway	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Poland	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Russian Fed	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Serbia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Slovenia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Slovenia	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Levovirin 17261	216/010-Ukraine	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending	
Levovirin 17261	216/010-US1	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	
Tiazofurin	216/011-Argentina	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	
Tiazofurin	216/011-Australia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	

Matters Moved to Subsidiary

Tiazofurin	216/011-Bosnia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Canada	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-China	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Croatia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Czech	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-EPO	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Hungary	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Israel	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Japan	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Korea	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Macedonia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Mexico	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-New Zealand	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Norway	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Poland	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Russia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Serbia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Slovakia	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-Ukraine	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending
Tiazofurin	216/011-US1	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - US	Allowed
Pyridostigmine	216/012-Argentina	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Australia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Bosnia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Brazil	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Canada	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-China	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Czech	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-EPO	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Hungary	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-India	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Israel	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Japan	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Korea	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Macedonia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Mexico	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Allowed
Pyridostigmine	216/012-New Zealand	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending
Pyridostigmine	216/012-Norway	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending

NOV 22 '01 12:49

7145359135

PAGE 13

Matters Moved to Subsidiary

Pyridostigmine	216/012-Poland	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending		
Pyridostigmine	216/012-Russia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending		
Pyridostigmine	216/012-Serbia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending		
Pyridostigmine	216/012-Slovakia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	11/10/17	20018
Pyridostigmine	216/012-Slovenia	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending		
Pyridostigmine	216/012-Ukraine	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Pending		
Pyridostigmine	216/012-US1	Multi-Valent Salts of Pyridostigmine	Patent - US	Pending		
G-rich Oligo Aptamer	216/013-Australia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Bosnia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Brazil	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Canada	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-China	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Czech	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-EPO	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Hungary	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-India	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Israel	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Japan	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Korea	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Macedonia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Mexico	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-New Zealand	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Norway	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Poland	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Russia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Serbia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Slovakia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Slovenia	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending		
G-rich Oligo Aptamer	216/013-Ukraine	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - US	Pending		
G-rich Oligo Aptamer	216/013-US1	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - US	Pending		
Ribavirin	216/019-US1	Systemic Dosing of Ribavirin or Levovirin via Pulmonary Route	Patent - Foreign	Pending		
Ribavirin	330.02-Argentina	Cytokine Related Treatments of Disease	Patent - Foreign	Pending		1737664
Ribavirin	330.02-Australia	Cytokine Related Treatments of Disease	Patent - Foreign	Pending		1742563
Ribavirin	330.02-Bosnia	Cytokine Related Treatments of Disease	Patent - Foreign	Pending		
Ribavirin	330.02-Brazil	Cytokine Related Treatments of Disease	Patent - Foreign	Pending		
Ribavirin	330.02-Canada	Cytokine Related Treatments of Disease	Patent - Foreign	Pending		
Ribavirin	330.02-China	Cytokine Related Treatments of Disease	Patent - Foreign	Pending		

SENT BY: N S2:44

11-2-1 10:44AM

13-

444 000 000

Matters Moved to Subsidiary

Ribavirin	330.02-Croatia	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Czech	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-EPO	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Hungary	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-India	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Israel	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Japan	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Korea	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Macedonia	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	5254526
Ribavirin	330.02-Mexico	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-New Zealand	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Norway	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Poland	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Russia	Cytokine Related Treatments of Disease	Patent - Foreign	Allowed	
Ribavirin	330.02-S. Africa	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Serbia	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Slovakia	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	01/13/18 9620003
Ribavirin	330.02-Slovenia	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-Ukraine	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	
Ribavirin	330.02-US1	Cytokine Related Treatments of Disease	Patent - US	Pending	
Ribavirin	330.02-US6	Cytokine Related Treatments of Disease	Patent - US	Pending	
Ribavirin	330.12-PCT	Modulation of Immune Response by Ribavirin	Patent - PCT	Pending	
Ribavirin	330.12-US2	Modulation of Immune Response by Ribavirin	Patent - US	Pending	
Adenazole	330.14-PCT	Use of 8-Cl-cAMP for Prevention of Resistance	Patent - PCT	Pending	
Adenazole	330.14-PRO2	Use of 8-Cl-cAMP for Prevention of Resistance	Patent - Provisional	Pending	05/28/00
Bicyclic Nucleoside	330.19-PCT	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - PCT	Pending	
Bicyclic Nucleoside	330.19-US1	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - US	Pending	
Ribavirin	330.22-PRO	Stimulation of Neuronal Growth using Ribavirin and Levovirin	Patent - Provisional	Pending	
Acycdonucleoside	330.26-PRO2	Acycdonucleosides Having 2'-Methylenealkyl Chain	Patent - Provisional	Pending	
Ribavirin	330.34-US1	Multiple Agent Modulation of Chemokines	Patent - US	Pending	
Methylidene Nucleoside	330.37-PRO2	Nucleosides and Oligonucleotides Containing Methylidene and Spiro	Patent - Provisional	Pending	
Conformationally Constrained Nucleosides	330.38-US1	Conformationally Constrained Nucleosides	Patent - US	Pending	
Conformationally Constrained Nucleosides	330.39-US1	Conformationally Constrained Nucleosides and Oligonucleotides	Patent - US	Allowed	
Purine-L-Nucleoside	330.44-PRO	Purine Nucleoside Analogs	Patent - Provisional	Pending	
Viramidine 10776	330.50-US1	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - Provisional	Pending	
PyridoPyrimidines 330.51-PRO		Pyrido(2,3-d)Pyrimidines and Pyrimido(4,5-d)Pyrimidine Nucleosides	Patent - Provisional	Pending	
Viramidine 10776	330.53-PRO	Immunomodulator of Lower Toxicity than Ribavirin (17261)	Patent - Provisional	Pending	

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TM No	APPL No
LEVOVIRIN	United States		75-850811
	European Community		
ADENAZOLE	United States		76-064924
	European Community		
VIRAMIDINE	United States		76-064998
	European Community		
TIAZOLE	United States		76-064923
	European Community		
SPAG	Benelux	466464	65264
	Canada	365911	620814
	Germany	1154633	V21070/10Wz
	Great Britain	1363233	1363233
	New Zealand	188829	188829
	Switzerland	367768	8025
	United States	1587615	776084
VIRAMID	China	293019	43337
	Dominican Republic	43456	
	Italy	604005	16,812 C/89
	Korea South		
	Mexico		553399/273965
	Norway	98749	113078
	Uruguay	230223	
VIRAZID	Great Britain	1307444	1307444
VIRAZIDE	Algeria	411025	272461
	Australia	A 465031	465031
	Austria	116040	3008/85
	Austria	411025	272461
	Benelux	331647	35570
	Benelux	411025	272461
	Chile	385572	
	Costarica	76339	
	Cuba		125742
	Dominican Republic	43455	
	Egypt	411025	272461
	El Salvador		

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TM No.	APPL No.
VIRAZIDE	European Community		614735
	France	411025	272461
	Germany	411025	272461
	Greece	86602	86602
	Guatemala	57439	
	Honduras	49381	
	India	295985	295985
	International	411025	272461
	Italy	411025	272461
	Italy	643267	17800 C/89
	Japan	3351362	048212/95
	Lebanon	29902	
	Lebanon	54225	238/118645
	Liechtenstein	411025	272461
	Maroco	411025	272461
	Mexico	289569	
	Monaco	411025	272461
	New Zealand	175557	175557
	Portugal		234309
	Romania	411025	272461
	San Marino	411025	272461
	Spain	411025	272461
	Switzerland	272461	
	United States	75/335,054	
	Yugoslavia	411025	272461
VIRAZIL	Russia	73967	95752
VIRAZOL	Russia		95700129
	Russia	RU 147,470	RU 95700129
VIRAZOLE	Argentina	1314866	
	Aruba	9753	12249
	Australia	A 439400	429400
	Austria	157095	AM 4722/94
	Benelux	414501	54442
	Bermuda	8094	
	Bolivia	49,685-C	
	Brazil		817166360
	Canada	201567	358987
	China	293014	43333
	China		9900136709

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TN.No	APPL.No
VIRAZOLE	Colombia	8459	
	Costarica	45986	
	Curacao	9753	
	Czechoslovakia	166787	55739/NNFA
	Denmark	03.779/1973	4582/72
	Dominican Republic	21304	
	Ecuador	539	
	Egypt	100,974	
	Finland	102579	853490
	France	1323031	758710
	Germany	1131270/5	V19549/5Wz
	Great Britain	1171757	1171757
	Greece	86603	86603
	Guatemala	50960	
	Honduras	45986	
	Hong Kong	442/1978	0107/1977
	India		480189
	Indonesia	206395	M/3004
	Ireland	145804	4871/90
	Italy	351751	3494677
	Japan	4109244	048211/95
	Jordan	4716	35159
	Korea South	214823	7835/90
	Korea South	207337	18079/89
	Kuwait	6890	7563
	Malaysia	85/04297	85/04297
	Malaysia	37813	94/05430
	Mexico	295722	
	New Zealand	161	160951
	Nicaragua	3,074 RPI	
	Norway	126421	85/3625
	Pakistan	87675	87675
	Panama	20,017	
		7378	
	Philippines	33738	26311
	Poland	53150	Z-71437
	Portugal	232265	232265
	RASA	4956	5065
	Salvador	187	
	Saudi Arabia	168/35	4328
	Singapore	S/4433/85	4433/85
	South Africa	85/7136	85/7136

Exhibit A - Trademarks Being Transferred to Subsidiary

MARK	COUNTRY	TN No	APPL No
VIRAZOLE	Spain	2058970	2058970
	Sweden	205801	85-06976
	Switzerland	342567	6151
	Taiwan	239658	72/43141
	Taiwan		88061506
	Thailand	TM 772	235590
	Trinidad	9049	
	United States	1929604	74/571024
	Venezuela	85,603-F	
	Yemen		2666
	Yugoslavia	30897	Z-761/85
	Zimbabwe	102/73	102/73

Matters Remaining in Patent

Topic	Matter ID	Title	Matter Type	Status	Expiration Date	Patent Number
Psoralens	169/204-US	5-Aminoethyl-4,4,8-Trisubstituted psoralens	Patent - US	Issued	07/29/00	4294822
Psoralens	169/205-US	4-Aminoethyl-4-Alkylsubstituted psoralens	Patent - US	Issued	07/29/00	4294847
Psoralens	171/149	Methoxsalen Dosage Forms	Patent - US	Issued	12/21/01	4454152
Psoralens	173/155-US	5-Aminoethylpsoralens	Patent - US	Issued	02/23/01	4929930
Psoralens	173/180-US	Photosensitizing Benzofuranacrylics	Patent - US	Issued	07/29/00	4279922
Psoralens	183/221-US	Psoralens Aminomethylation	Patent - US	Issued	07/14/08	4960770
Psoralens	204/178-US1	Oxoralten-Ultra	Patent - US	Issued	03/28/04	4913901
Radiation Vial	218/004-Benelux	Design for Vial	Patent - Foreign	Allowed	03/24/02	28337-60
Radiation Vial	218/004-France	Design for Vial	Patent - Foreign	Allowed	03/27/22	971945
Radiation Vial	218/004-Germany	Design for Vial	Patent - Foreign	Issued		M 87 03 148.6
Radiation Vial	218/004-Italy	Design for Vial	Patent - Foreign	Pending		
Radiation Vial	218/004-Russian Fed	Design for Vial	Patent - Foreign	Issued	04/28/12	45830
Radiation Vial	218/004-Spain	Design for Vial	Patent - Foreign	Issued	12/22/07	140049
Radiation Vial	218/004-Sweden	Design for Vial	Patent - Foreign	Issued	04/29/02	63 087
Radiation Vial	218/004-UK	Design for Vial	Patent - US	Issued	08/07/22	2061181
Radiation Vial	218/004-DE5	Design for Vial	Patent - US	Issued	04/27/13	408957
Radiation Vial	218/005-EPO	Packaging with Centrifuge Tube	Patent - Foreign	Pending		
Radiation Vial	218/005-US	Packaging With Centrifuge Tube	Patent - US	Issued	07/21/18	5763832
UV Device	173/156-DE5	Ultraviolet Lamp	Patent - US	Issued		DE5268287
	180/050-US	Process for introducing Vitamin B-12...	Patent - US	Issued	10/18/01	4432975
	174/147-US	Compositions & Method for Simultaneous ...	Patent - US	Issued	05/23/04	4672028
	174/149-US	Direct Reading Automatic Pipette	Patent - US	Issued	10/31/03	4563907
	178/131-US	Compositions and Methods for Multiple ...	Patent - US	Issued	06/08/07	5001072
	188/121-US	Manifold Construction	Patent - US	Issued	09/23/12	5334352
	188/299-US	Antiparasitic 9'-Sulfamoyl Nucleosides	Patent - US	Issued	02/27/09	4982426
	188/301-US	T Cell Immunopotentiator	Patent - US	Issued	10/04/06	4950847
	188/304-DE5	Infant Medical Hood	Patent - US	Issued		DE5322652
	199/001-US	Scavenging Medical Hood	Patent - US	Issued	07/28/09	4849714
	201/001-US	Immunometric Assay Using Monoclonal A	Patent - US	Issued	08/04/00	4376110
	201/002-US	Assay for the Free Portion of Substance ...	Patent - US	Issued	09/22/00	4368143
	201/003-US	Simultaneous Radioassay of Folate and ...	Patent - US	Issued	02/12/01	4423154
	201/004-US	Assay Process with Non-Bollingsdenstr ...	Patent - US	Issued	03/30/01	4418151
	201/005-US	Preparation of Samples for Vitamin B12	Patent - US	Issued	04/06/01	4451571
	201/006-US	Immunometric Assay Using Monoclonal ...	Patent - US	Issued	05/24/01	4468530
	201/007-US	Immunoprecipitation Assay of Immunoglo ...	Patent - US	Issued	08/19/05	4618580
	201/008-US	9-(8-D-Ribofurandyl) Purine-6-Carboxam ...	Patent - US	Issued	09/26/00	4328338

NOV 02 '01 12:54

7145359136

PAGE 21

Matters Remaining in Parent

201/040-US	Cells Collection and Sample Handling ...	Patent - US	Issued	07/21/09	5261384
201/050-US	Process for Treating Wet Fat Biological ...	Patent - US	Issued	08/19/09	4707369
201/051-US	Method for the Production of 2'-Deoxy ...	Patent - US	Issued	01/15/07	4766137
201/052-US	Rapid and Automatic Fluorescence ...	Patent - US	Issued	07/13/03	6626664
201/056-US	Pipette Tip Pickup Apparatus	Patent - US	Issued	11/12/11	5963790
201/183-US	Small Particle Aerosol Generator ...	Patent - US	Issued	03/07/08	4646611
213/086-US1	Improved Utilization of Virus	Patent - US	Issued	08/25/18	5766290
218/030-US	Two-Step Process for Coating Antibodies	Patent - US	Issued	06/26/12	5390600
330.80-PRO	Kits With Multiple Cots	Patent - Provisional	Pending		

SENT BY: 11/02/2001

11/02/2001 10:00AM

1/26/01

2 of 2

ICN Patents Schedules-02d (as of Aug 7, 2009).xls

PATENT
REEL: 015819 FRAME: 0618

Exhibit C

1. All equipment forming ICN Pharmaceuticals, Inc.'s AS-400 mainframe computer system.
2. All equipment, materials, supplies, data, journals and records related to ICN Pharmaceuticals, Inc.'s dosimetry services operations.

Resolutions of the
Board of Directors of
ICN Pharmaceuticals, Inc.

WHEREAS, on August 7, 2000, the Board of Directors of this Corporation previously adopted resolutions (the "August 2000 Resolutions") contributing to Ribapharm Inc. ("Ribapharm") all of the Corporation's rights, title and interest in the Contributed Assets (as defined in the August 2000 Resolutions), including, without limitation, the Costa Mesa Facility (as defined in the August 2000 Resolutions); furniture, equipment, materials, supplies, data, journals and records located at the Costa Mesa Facility and related to or used in connection with, U.S. research and development activities (the "Personal Property"); and chemical compounds related to U.S. research and development activities.

NOW THEREFORE BE IT RESOLVED, that the August 2000 Resolutions, to the extent such resolutions contributed to Ribapharm the Costa Mesa facility, are rescinded, it being understood that the contribution of all of the other Contributed Assets (including without limitation the Personal Property) remains in full force and effect;

RESOLVED FURTHER, that the officers of the Corporation be, and each of them hereby is, authorized, in the name and on behalf of the Corporation, to enter into a leasing arrangement with Ribapharm, with respect to a portion of the Costa Mesa facility, under terms they may deem necessary or advisable, such authorization to be conclusive upon the execution and delivery of the lease; and

RESOLVED FURTHER, that the Corporation hereby contributes to Ribapharm all of its rights, title and interest in ICN2001-3 (to be named Hepavir B), a nucleoside compound that the Corporation licensed from Metabasis Therapeutics, Inc. along with all related patents and patent applications, trademarks and trademark applications, goodwill, trade secrets, records, journals, data, equipment, materials and supplies;

RESOLVED FURTHER, that the Corporation hereby contributes to Ribapharm all of its rights, title and interest in IL-12, a compound that it may have received pursuant to an Exchange Agreement and a Transfer Agreement by and between Hoffman-La Roche and F. Hoffman-La Roche Ltd. and Ribapharm and ICN Puerto Rico, dated June 29, 2001, along with all related patents and patent applications, trademarks and trademark applications, goodwill, trade secrets, records, journals, data, equipment, materials and supplies; and

RESOLVED FURTHER, that the officers of this Corporation are authorized on behalf of this Corporation to enter into any agreements or execute any instruments useful or necessary to effect the intent of the foregoing resolutions.

ICN Files Transferred to Ribapharm

SCHEDULE C

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0002AR	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P98 01 03953	Th1/Th2 (broad), Ribavirin
100848.0002AR2	Novel Nucleosides	Patent - Foreign	Pending	P 00 01 04639	Th1/Th2 (narrow), Ribavirin
100848.0002AU	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	60238/98	Th1/Th2 (broad), Ribavirin
100848.0002AU2	Novel Nucleosides	Patent - Foreign	Allowed	48659/00	Th1/Th2 (narrow), Ribavirin
100848.0002BA	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	BAP 99398A	Th1/Th2 (broad), Ribavirin
100848.0002BA2	Novel Nucleosides	Patent - Foreign	Pending	BAP-00612A	Th1/Th2 (narrow), Ribavirin
100848.0002BR	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P19807473-3	Th1/Th2 (broad), Ribavirin
100848.0002BR2	Novel Nucleosides	Patent - Foreign	Pending	P19816127-0	Th1/Th2 (narrow), Ribavirin
100848.0002CA	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2278158	Th1/Th2 (broad), Ribavirin
100848.0002CA2	Novel Nucleosides	Patent - Foreign	Pending		Th1/Th2 (narrow), Ribavirin
100848.0002CN2	Novel Nucleosides	Patent - Foreign	Pending	00121912.X	Th1/Th2 (narrow), Ribavirin
100848.0002CN3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	126807.4	Th1/Th2 (broad), Ribavirin
100848.0002CZ2	Novel Nucleosides	Patent - Foreign	Pending	PV 2000-3804	Th1/Th2 (narrow), Ribavirin
100848.0002CZ3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	PV 2000-3805	Th1/Th2 (broad), Ribavirin
100848.0002EPO	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	98903474.9	Th1/Th2 (broad), Ribavirin
100848.0002EPO2	Novel Nucleosides	Patent - Foreign	Pending	00118252.6	Th1/Th2 (narrow), Ribavirin
100848.0002HK	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	00102855.0	Th1/Th2 (broad), Ribavirin
100848.0002HK2	Novel Nucleosides	Patent - Foreign	Pending	01104385.4	Th1/Th2 (narrow), Ribavirin
100848.0002HR2	Cytokine Related Treatments of Disease	Patent - Foreign	Allowed	P20000421A	Th1/Th2 (broad), Ribavirin
100848.0002HR3	Novel Nucleosides	Patent - Foreign	Allowed	P20000423A	Th1/Th2 (narrow), Ribavirin
100848.0002HU	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P0001526	Th1/Th2 (broad), Ribavirin
100848.0002HU2	Novel Nucleosides	Patent - Foreign	Pending	P00 02453	Th1/Th2 (narrow), Ribavirin
100848.0002IL2	Novel Nucleosides	Patent - Foreign	Pending	137393	Th1/Th2 (narrow), Ribavirin
100848.0002IL3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	137392	Th1/Th2 (broad))
100848.0002IN	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	1614/Ca/98	Th1/Th2 (broad), Ribavirin
100848.0002IN2	Novel Nucleosides	Patent - Foreign	Pending	646/CAL/2000	Th1/Th2 (narrow), Ribavirin
100848.0002JP	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	531245/98	Th1/Th2 (broad), Ribavirin
100848.0002JP2	Novel Nucleosides	Patent - Foreign	Pending	2001-155321	Th1/Th2 (narrow), Ribavirin
100848.0002KR	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	1999-7006393	Th1/Th2 (broad), Ribavirin
100848.0002KR2	Novel Nucleosides	Patent - Foreign	Pending	(PCT) 2001-7004524	Th1/Th2 (narrow), Ribavirin
100848.0002MK	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	P-01/99	Th1/Th2 (broad), Ribavirin
100848.0002MK2	Novel Nucleosides	Patent - Foreign	Pending	P-20000059	Th1/Th2 (narrow), Ribavirin
100848.0002MX	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	996418	Th1/Th2 (broad), Ribavirin
100848.0002MX2	Novel Nucleosides	Patent - Foreign	Pending	09527	Th1/Th2 (narrow), Ribavirin
100848.0002NO2	Novel Nucleosides	Patent - Foreign	Pending	2000 4327	Th1/Th2 (narrow), Ribavirin
100848.0002NO3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2000 4329	Th1/Th2 (broad), Ribavirin
100848.0002NZ2	Novel Nucleosides	Patent - Foreign	Issued	505531	Th1/Th2 (narrow), Ribavirin
100848.0002NZ3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	505530	Th1/Th2 (broad), Ribavirin
100848.0002PL	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P.336 579	Th1/Th2 (broad), Ribavirin
100848.0002RU2	Novel Nucleosides	Patent - Foreign	Pending	RU 2000122128	Th1/Th2 (narrow), Ribavirin
100848.0002RU3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	RU 2000122127	Th1/Th2 (broad), Ribavirin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0002SB	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	P-615/98	Th1/Th2 (broad), Ribavirin
100848.0002SB2	Novel Nucleosides	Patent - Foreign	Pending	P-434/2000	Th1/Th2 (narrow), Ribavirin
100848.0002SI	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	P-9820003	Th1/Th2 (broad), Ribavirin
100848.0002SK	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	PV 940-99	Th1/Th2 (broad), Ribavirin
100848.0002SK2	Novel Nucleosides	Patent - Foreign	Pending	PV 1487-2000	Th1/Th2 (narrow), Ribavirin
100848.0002UA2	Novel Nucleosides	Patent - Foreign	Pending	2000073981/I	Th1/Th2 (narrow), Ribavirin
100848.0002UA3	Cytokine Related Treatments of Disease	Patent - Foreign	Pending	2000073980/I	Th1/Th2 (broad), Ribavirin
100848.0002US10	Cytokine Related Treatments of Disease	Patent - US	Pending	10/136745	Th1/Th2 (broad), Ribavirin
100848.0002US6	Cytokine Related Treatments of Disease	Patent - US	Allowed	09/467443	Th1/Th2 (broad), Ribavirin
100848.0002US7	Novel Nucleosides	Patent - US	Allowed	09/594647	Th1/Th2 (narrow), Ribavirin
100848.0002US8	Cytokine Related Treatments of Disease	Patent - US	Pending	09/594372	Th1/Th2 (broad), Ribavirin
100848.0002US9	Cytokine Related Treatments of Disease	Patent - US	Pending	09/595448	Th1/Th2 (broad), Ribavirin
100848.0002ZA	Cytokine Related Treatments of Disease	Patent - Foreign	Issued	986641	Th1/Th2 (broad), Ribavirin
100848.0012AR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	668761	Ribavirin
100848.0012AU	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	24833/00	Ribavirin
100848.0012BA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	BAP01842A	Ribavirin
100848.0012BR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P19917090-6	Ribavirin
100848.0012CA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2357735	Ribavirin
100848.0012CN	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	99815897.6	Ribavirin
100848.0012CZ	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	PV 2001-2519	Ribavirin
100848.0012DE	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	299 24 200.5	Ribavirin
100848.0012EPO	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	99968155.6	Ribavirin
100848.0012HK	Modulation of Immune Response by Ribavirin	Patent - Foreign	Allowed	2102923.6	Ribavirin
100848.0012HR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P20010496A	Ribavirin
100848.0012HU	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P0200027	Ribavirin
100848.0012IL	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	144130	Ribavirin
100848.0012IN	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending		Ribavirin
100848.0012JP	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2000-595690	Ribavirin
100848.0012KR	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	(PCT) 2001-7009609	Ribavirin
100848.0012MK	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P/PCT20010/060	Ribavirin
100848.0012MX	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	PA/a/2001/007211	Ribavirin
100848.0012NO	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2001 3529	Ribavirin
100848.0012NZ	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	512879	Ribavirin
100848.0012PL	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending		Ribavirin
100848.0012RU	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	RU 2001119056	Ribavirin
100848.0012SB	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P-524/01	Ribavirin
100848.0012SI	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	P-9920099	Ribavirin
100848.0012SK	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	PV-2001-1009	Ribavirin
100848.0012UA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	2001074909/M	Ribavirin
100848.0012US3	Modulation of Immune Response by Ribavirin	Patent - US	Pending	10/154189	Ribavirin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0012ZA	Modulation of Immune Response by Ribavirin	Patent - Foreign	Pending	20015595	Ribavirin
100848.0019AR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	1589903	Bicyclic Nucleosides
100848.0019AU	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	40100/99	Bicyclic Nucleosides
100848.0019BA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	BAP00664A	Bicyclic Nucleosides
100848.0019BR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	PI 9911596-4	Bicyclic Nucleosides
100848.0019CA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2333380	Bicyclic Nucleosides
100848.0019CN	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	99809057.3	Bicyclic Nucleosides
100848.0019CZ	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	PV 2000-4181	Bicyclic Nucleosides
100848.0019EPO	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	99923288.7	Bicyclic Nucleosides
100848.0019HK	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	1102939.9	Bicyclic Nucleosides
100848.0019HR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P20000751A	Bicyclic Nucleosides
100848.0019HU	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P0102152	Bicyclic Nucleosides
100848.0019IL	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	139420	Bicyclic Nucleosides
100848.0019IN	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending		Bicyclic Nucleosides
100848.0019JP	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2000-550331	Bicyclic Nucleosides
100848.0019KR	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	(PCT) 2000-7013335	Bicyclic Nucleosides
100848.0019MK	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending		Bicyclic Nucleosides
100848.0019MX	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	11473	Bicyclic Nucleosides
100848.0019NO	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2000 5938	Bicyclic Nucleosides
100848.0019NZ	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	507913	Bicyclic Nucleosides
100848.0019PL	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P.344303	Bicyclic Nucleosides
100848.0019RU	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	RU 200129663	Bicyclic Nucleosides
100848.0019SB	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	P-736/00	Bicyclic Nucleosides
100848.0019SI	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Issued	P-9920038	Bicyclic Nucleosides
100848.0019SK	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	PV 2000-1743	Bicyclic Nucleosides
100848.0019UA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Pending	2000116545/M	Bicyclic Nucleosides
100848.0019US1	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - US	Allowed	09/451708	Bicyclic Nucleosides
100848.0019US2	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - US	Pending	1446636	Bicyclic Nucleosides
100848.0019ZA	Novel Nucleosides Having Bicyclic Sugar Moiety	Patent - Foreign	Allowed	20006315	Bicyclic Nucleosides
100848.0034US1	Multiple Agent Modulation of Chemokines	Patent - US	Pending	09/561402	Ribavirin
100848.0038US1	Conformationally Constrained Nucleosides	Patent - US	Pending	09/569183	Conformationally Constrained Nucleosides
100848.0039US1	Conformationally Locked Nucleosides and Oligonucleotides	Patent - US	Issued	09/309742	Conformationally Locked Nucleosides
100848.0048AR	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P02 01 00590	Pyrrolo-Pyrimidine 17739
100848.0048AU	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	70618/00	Pyrrolo-Pyrimidine 17739
100848.0048BA	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	BAP02995A	Pyrrolo-Pyrimidine 17739
100848.0048BR	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PI0013642-5	Pyrrolo-Pyrimidine 17739
100848.0048CA	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0048CN	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0048CZ	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PV 2002-727	Pyrrolo-Pyrimidine 17739

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0048EP	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	959267.6	Pyrrolo-Pyrimidine 17739
100848.0048HR	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P20020163A	Pyrrolo-Pyrimidine 17739
100848.0048HU	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0048IL	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	147908	Pyrrolo-Pyrimidine 17739
100848.0048IN	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	IN/PCT/2002/00228/DE	Pyrrolo-Pyrimidine 17739
100848.0048JP	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2001-530332	Pyrrolo-Pyrimidine 17739
100848.0048KR	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	(PCT) 2002-7002570	Pyrrolo-Pyrimidine 17739
100848.0048MK	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0048MX	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PA/a/2002/001753	Pyrrolo-Pyrimidine 17739
100848.0048NO	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2002 0931	Pyrrolo-Pyrimidine 17739
100848.0048NZ	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	516941	Pyrrolo-Pyrimidine 17739
100848.0048PL	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0048RU	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2002103501	Pyrrolo-Pyrimidine 17739
100848.0048SB	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P-144/02	Pyrrolo-Pyrimidine 17739
100848.0048SI	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	200020035	Pyrrolo-Pyrimidine 17739
100848.0048SK	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	PV 177-2002	Pyrrolo-Pyrimidine 17739
100848.0048UA	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	2002021355	Pyrrolo-Pyrimidine 17739
100848.0048US1	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - US	Pending	10/048795	Pyrrolo-Pyrimidine 17739
100848.0048ZA	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrrolo-Pyrimidine 17739
100848.0050AR	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - Foreign	Pending	P02 01 02829	Viramidine/10776
100848.0050PCT	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - PCT	Superceded	PCT/US01/05172	Viramidine/10776
100848.0050US1	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - US	Allowed	09/595365	Viramidine/10776
100848.0050US2	Heterocyclic Aromatic Compounds and Uses Thereof	Patent - US	Pending	10/095665	Viramidine/10776
100848.0051PCT	Pyrido[2,3-d]Pyrimidine and Pyrimido[4,5-d]Pyrimidine Nucleosides	Patent - PCT	Pending	PCT/US01/41242	Pyrido-Pyrimidine 14686
100848.0056AR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	P02 01 00253	Levovirin 17261
100848.0056AU	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	22816/01	Levovirin 17261
100848.0056BA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	BAP021072A	Levovirin 17261
100848.0056BR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PI0016163-2	Levovirin 17261
100848.0056CA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056CN	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056CZ	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PV 2002-968	Levovirin 17261
100848.0056EP	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056HR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	P20020486A	Levovirin 17261
100848.0056HU	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0056ID	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	W-00200201701	Levovirin 17261
100848.0056IL	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	148510	Levovirin 17261
100848.0056IN	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056JP	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056KR	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056MK	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056MX	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056MY	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PI 20021021	Levovirin 17261
100848.0056NO	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	2002 2816	Levovirin 17261
100848.0056NZ	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	517633	Levovirin 17261
100848.0056PH	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056PL	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056RU	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056SB	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056SG	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	2002 01486-8	Levovirin 17261
100848.0056SI	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	P-200020046	Levovirin 17261
100848.0056SK	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending	PV 625-2002	Levovirin 17261
100848.0056UA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0056US1	Treatment of Viral Infections With Levovirin	Patent - US	Pending	09/471513	Levovirin 17261
100848.0056US2	Treatment of Viral Infections With Levovirin	Patent - US	Pending		Levovirin 17261
100848.0056ZA	Treatment of Viral Infections Using Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0070DE	Nucleoside Compounds and Uses Thereof	Patent - Foreign	Pending	201 21 305.2	Levovirin, Viramidine
100848.0070EPO1	Antiviral Pro-drug	Patent - Foreign	Pending	1924208	Pro-drugs, Levovirin, Viramidine
100848.0070EPO2	Nucleoside Compounds and Uses Thereof	Patent - Foreign	Pending	1920509.5	Levovirin, Viramidine
100848.0070PCT1	Antiviral Pro-drug	Patent - PCT	Pending	PCT/US01/08769	Pro-drugs, Levovirin, Viramidine
100848.0070PCT2	Nucleoside Compounds and Uses Thereof	Patent - PCT	Pending	PCT/US01/08713	Levovirin, Viramidine
100848.0070US1	Nucleoside Compounds and Uses Thereof	Patent - US	Pending	981287	Levovirin, Viramidine
100848.0071	RIBAPHARM	TMK - US	Allowed	76/071869	
100848.0074US1	Rapid Generation of Diverse Nucleoside and Nucleotide Libraries	Patent - US	Pending	09/904248	Parallel Synthesis
100848.0087PCT	Improved Specificity in Treatment of Diseases	Patent - PCT	Pending	PCT/US00/33454	Viramidine
100848.0096	Pegylated Nucleosides	Patent - US	Not filed		
100848.0097AR	Methods and Compositions for Levovirin	Patent - Foreign	Pending	P02 01 00584	Levovirin 17261
100848.0097AU	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097BA	Methods and Compositions for Levovirin	Patent - Foreign	Pending	BAP021071A	Levovirin 17261
100848.0097BR	Methods and Compositions for Levovirin	Patent - Foreign	Pending	PI0016162-4	Levovirin 17261
100848.0097CA	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097CN	Methods and Compositions for Levovirin	Patent - Foreign	Pending	00817416.4	Levovirin 17261
100848.0097CZ	Methods and Compositions for Levovirin	Patent - Foreign	Pending	2002-2112	Levovirin 17261
100848.0097EP	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0097HR	Methods and Compositions for Levovirin	Patent - Foreign	Pending	P20020485A	Levovirin 17261
100848.0097HU	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097ID	Methods and Compositions for Levovirin	Patent - Foreign	Pending	W-00200201702	Levovirin 17261
100848.0097IL	Methods and Compositions for Levovirin	Patent - Foreign	Pending	148514	Levovirin 17261
100848.0097IN	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097JP	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097KR	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097MK	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097MX	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097MY	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097NO	Methods and Compositions for Levovirin	Patent - Foreign	Pending	2002 2969	Levovirin 17261
100848.0097NZ	Methods and Compositions for Levovirin	Patent - Foreign	Pending	517634	Levovirin 17261
100848.0097PH	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097PL	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097RU	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097SB	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097SG	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097SI	Methods and Compositions for Levovirin	Patent - Foreign	Pending	P-200020047	Levovirin 17261
100848.0097SK	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097UA	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0097US	Methods and Compositions for Levovirin	Patent - US	Pending		Levovirin 17261
100848.0097ZA	Methods and Compositions for Levovirin	Patent - Foreign	Pending		Levovirin 17261
100848.0100PCT	Nucleoside Analogs With Carboxamidine Modified Bicyclic Base	Patent - PCT	Pending	PCT/US01/40148	Viramidine
100848.0102PCT	Nucleoside Vaccine Adjuvants	Patent - PCT	Pending		Nucleoside Adjuvant
100848.0103AR	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	P02 01 02803	Pyrido-Pyrimidine 17739
100848.0103MY	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending		Pyrido-Pyrimidine 17739
100848.0103PCT	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - PCT	Pending	PCT/US02/06347	Pyrido-Pyrimidine 17739
100848.0103TW	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - Foreign	Pending	91115523	Pyrido-Pyrimidine 17739
100848.0103US1	Pyrrolo[2,3-D]pyrimidine Nucleoside Analogs	Patent - US	Pending	09/797549	Pyrido-Pyrimidine 17739
100848.0105PCT	Methods of Drug Delivery to Hepatocytes and Treatment of Flaviviridae Infections	Patent - PCT	Pending	PCT/US01/26057	Viramidine
100848.0106PRO2	Treatment of Gastroesophageal Reflux Disease	Patent - Provisional	Pending	60/377290	Photodynamic
100848.0112PCT	MCC Nucleoside Libraries and Compounds	Patent - PCT	Not filed		
100848.0112PRO	MCC Nucleoside Libraries and Compounds	Patent - Provisional	Pending	60/342337	
100848.0113PCT	Deazapurine Libraries and Compounds	Patent - PCT	Not filed		
100848.0113PRO	Deazapurine Libraries and Compounds	Patent - Provisional	Pending	60/342410	
100848.0114PCT	Substituted Cytidine Libraries and Compounds	Patent - PCT	Not filed		

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0114PRO	Substituted Cytidine Libraries and Compounds	Patent - Provisional	Pending	60/342336	
100848.0115PCT	Unusual Nucleoside Libraries & Compounds for Antiviral & Anticancer Agents	Patent - PCT	Not filed		
100848.0115PRO	Modified Nucleoside Analog Libraries and Compounds	Patent - Provisional	Pending	60/342407	
100848.0116PCT	Substituted Purine Libraries and Compounds	Patent - PCT	Not filed		
100848.0116PRO	Substituted Purine Libraries and Compounds	Patent - Provisional	Pending	60/342441	
100848.0117PRO	Nucleoside Analogs Libraries and Compounds	Patent - Provisional	Pending	60/342452	
100848.0118PRO	MB6866 Invention	Patent - Provisional	Not filed		
100848.0126PRO	Direct and Specific Inhibitors for RNA/DNA in the De Novo Synthesis	Patent - Provisional	Pending	60/335309	
100848.0127PRO	Bivalent Inhibitors for HCV Polymerase	Patent - Provisional	Pending	60/346680	
100848.0130PRO	Yellow Laser for Prostrate Treatment	Patent - Provisional	Not filed		
100848.0131PRO	High-Load Controlled Release Of Nucleoside Drugs	Patent - Provisional	Pending	60/335099	
100848.0132PRO	Antiviral Combinations With Organ Specificity	Patent - Provisional	Pending	60/335096	
100848.0133PRO	Antiviral Combinations Using L-Nucleosides	Patent - Provisional	Pending	60/335097	
100848.0134PRO	Antiviral Combinations Including Cytokines	Patent - Provisional	Pending	60/335095	
100848.0136PRO	Neurological Effects of Ribavirin and RSV	Patent - Provisional	Pending	60/333311	Corp Devel
100848.0145PRO	Modified Nucleoside Library Compounds and Uses as Antiviral Agents	Patent - Provisional	Pending	60/350296	
100848.0146PRO	Tricyclic Nucleoside Libraries	Patent - Provisional	Pending	60/350249	
100848.0179PRO	Very Slow Time Release Interferon	Patent - Provisional	Not filed		
100848.0182PRO	Dinucleotide Compounds	Patent - Provisional	Pending	60/373735	
100848.0183PRO	Antiviral Compositions and Methods using IFN-gamma	Patent - Provisional	Pending	60/364429	
100848.0184US	RIBAPHARM X	Trademark - US	Not filed		
100848.0185PRO	Nucleoside Libraries, Synthetic Strategies, and Uses of Compounds Therein	Patent - Provisional	Pending	60/364681	

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.0186PRO	Phosphonate Nucleosides and Methods Therefor	Patent - Provisional	Pending	60/377024	Phosphonate Nucleosides
100848.0200PRO	Drug Combinations with PMEA and PMEA Prodrugs	Patent - Provisional	Not filed		
100848.0201PRO	Drug Combinations with IL-12	Patent - Provisional	Not filed		
100848.0204PRO	Sugar Modified Nucleosides as RNA-Polymerase Inhibitors	Patent - Provisional	Not filed		
100848.0205PRO	Protein Kinase Inhibitors	Patent - Provisional	Pending		Kinase Inhibitors
100848.0209PRO	Kinase Inhibitors	Patent - Provisional	Pending		Kinase Inhibitors
100848.169097AT	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097CH	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097DE	Ribavirin (Human Antiviral use)	Patent - Foreign	Issued	DD 261094	Ribavirin
100848.169097DE2	Ribavirin Human Use	Patent - Foreign	Pending	DE 3588232.8-08	Ribavirin
100848.169097EP2	Ribavirin Human Use	Patent - Foreign	Issued	94118300.6	Ribavirin
100848.169097FR	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097HK	Ribavirin Human Use	Patent - Foreign	Issued	98111842	Ribavirin
100848.169097IT	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097JP	Ribavirin Human Use	Patent - Foreign	Issued	122351/85	Ribavirin
100848.169097NL	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097OPP	Ribavirin Human Use European Opposition	Patent - Foreign	Pending		Ribavirin
100848.169097SE	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.169097UK	Ribavirin Human Use	Patent - Foreign	Pending		Ribavirin
100848.182262CD1	8-Chloroadenosine 3',5'-Cyclic monophosphatete Preparations	Patent - Foreign	Issued	616661	Adenazole
100848.184002JP	Tiazole	Patent - Foreign	Issued	114152/82	Tiazofurin
100848.185103AR	Sulfasine	Patent - Foreign	Issued	312708	Sulfasine
100848.185103AT	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103BE	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103CA	Sulfasine	Patent - Foreign	Issued	585590	Sulfasine
100848.185103CH	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103DE	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103ES	Sulfasine	Patent - Foreign	Issued	88 03792	Sulfasine
100848.185103FR	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103GB	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103GR	Sulfasine	Patent - Foreign	Issued	880100833	Sulfasine
100848.185103IT	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103JP	Sulfasine	Patent - Foreign	Issued	500646/1989	Sulfasine
100848.185103KR	Sulfasine	Patent - Foreign	Issued	89-701531	Sulfasine
100848.185103LU	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.185103MX	Sulfasine	Patent - Foreign	Issued	14111	Sulfasine
100848.185103NL	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103NZ	Sulfasine	Patent - Foreign	Issued		Sulfasine
100848.185103SE	Sulfasine	Patent - Foreign	Issued	89900773.6	Sulfasine
100848.185103US	Sulfasine	Patent - US	Issued	275113	Sulfasine
100848.195183NS3	Adenazole (8-Cl-cAMP)	Patent - US	Issued	67420	Adenazole
100848.195183NS4	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/225097	Adenazole
100848.195183NS5	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/937020	Adenazole
100848.195183US5	Adenazole (8-Cl-cAMP)	Patent - US	Issued	08/438537	Adenazole
100848.198296US	Virazole Derivative	Patent - US	Issued	750026	Ribavirin
100848.198297US	Substituted Pyrimido [5,4-D] Pyrimidine . . .	Patent - US	Issued	1563056	Pyrido-Pyrimidine 14686
100848.198298US1	Sulfenamide, Sulnamide and Sulfonamide Purines and Processes of Making	Patent - US	Issued	07/275113	Sulfasine
100848.198300US	Treatment of malignant Tumors with 2-(B-D-Ribofuranosylthiazole-4-Carboxamide & Related Compounds (Tiazofurin)	Patent - US	Issued	706084	Tiazofurin
100848.198302US	8-Chloroadenosine 3',5'-Cyclic Monophosphate Preparations	Patent - US	Issued	136407	Adenazole
100848.201069BE	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069CA	Oncozole	Patent - Foreign	Issued	433341	Oncozole
100848.201069CH	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069DE	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069DK	Oncozole	Patent - Foreign	Issued	663/84	Oncozole
100848.201069FR	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069IE	Oncozole	Patent - Foreign	Issued	1779/83	Oncozole
100848.201069IT	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069JP	Oncozole	Patent - Foreign	Issued	149739/83	Oncozole
100848.201069LU	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069NL	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069SE	Oncozole	Patent - Foreign	Issued	83304702	Oncozole
100848.201069US	Oncozole	Patent - US	Issued	06/821176	Oncozole
100848.201086PT1	Oncozole	Patent - Foreign	Issued		Oncozole
100848.201092DK	Selenazole compounds and method for production	Patent - Foreign	Issued	1299/83	Selenazole
100848.201223AR	Tiazofurin & Ribavirin	Patent - Foreign	Pending	328.234	Tiazofurin
100848.201223AT	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223AU	Tiazofurin & Ribavirin	Patent - Foreign	Issued	67827/94	Tiazofurin
100848.201223CA	Tiazofurin & Ribavirin	Patent - Foreign	Pending	2161970	Tiazofurin
100848.201223CH	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223DE	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223E	Tiazofurin & Ribavirin	Patent - Foreign	Issued	94916011.3-2107	Tiazofurin
100848.201223ES	Tiazofurin & Ribavirin	Patent - Foreign	Pending	2144703	Tiazofurin
100848.201223FR	Tiazofurin & Ribavirin	Patent - Foreign	Not filed		Tiazofurin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.201223GB	Tiazofurin & Ribavirin	Patent - Foreign	Pending	GB 0707479	Tiazofurin
100848.201223HK	Tiazofurin & Ribavirin	Patent - Foreign	Issued	98112731.2	Tiazofurin
100848.201223JP	Tiazofurin & Ribavirin	Patent - Foreign	Issued	5235531/19994	Tiazofurin
100848.201223KR	Tiazofurin & Ribavirin	Patent - Foreign	Issued	95-705126	Tiazofurin
100848.201223MX	Tiazofurin & Ribavirin	Patent - Foreign	Pending	94 3666	Tiazofurin
100848.201223NL	Tiazofurin & Ribavirin	Patent - Foreign	Pending		Tiazofurin
100848.201223NZ	Tiazofurin & Ribavirin	Patent - Foreign	Issued	266359	Tiazofurin
100848.201223RU	Tiazofurin & Ribavirin	Patent - Foreign	Issued	95122466	Tiazofurin
100848.201223US	Tiazofurin & Ribavirin	Patent - US	Issued	08/065,348	Tiazofurin
100848.206165US	Selenazole	Patent - US	Issued	07/612267	Selenazole
100848.206166US1	Selenazole	Patent - US	Issued	07/612078	Selenazole
100848.207075US	Selenazole	Patent - US	Issued	07/629287	Selenazole
100848.213001AU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	690394	Sugar Mod Nucleosides
100848.213001CA	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	2202280	Sugar Mod Nucleosides
100848.213001CA2	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	2307311	Sugar Mod Nucleosides
100848.213001CN	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	95196962.5	Sugar Mod Nucleosides
100848.213001CZ	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	PV 1997-1291	Sugar Mod Nucleosides
100848.213001E	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	95939864.5-2110	Sugar Mod Nucleosides
100848.213001HK	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	98109044	Sugar Mod Nucleosides
100848.213001HU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	P9702445	Sugar Mod Nucleosides
100848.213001JP	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	515519/96	Sugar Mod Nucleosides
100848.213001KR	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	97-702924	Sugar Mod Nucleosides
100848.213001MX	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	97 3192	Sugar Mod Nucleosides
100848.213001PL	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	P.319944 PCT/US95/14	Sugar Mod Nucleosides
100848.213001RU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	RU 97108591	Sugar Mod Nucleosides
100848.213001SK	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Pending	PV 548-97	Sugar Mod Nucleosides
100848.213001UA	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	97041994/M	Sugar Mod Nucleosides

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.213001US1	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	1448401	Sugar Mod Nucleosides
100848.213001US2	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	08/552363	Sugar Mod Nucleosides
100848.213001US3	Sugar Modified Nucleosides and Their Uses For Synt	Patent - US	Issued	08/766991	Sugar Mod Nucleosides
100848.213001US4	Sugar Modified Nucleosides and Oligonucleotides	Patent - US	Pending	09/697545	Sugar Mod Nucleosides
100848.213001YU	Sugar Modified Nucleosides and Their Uses For Synt	Patent - Foreign	Issued	P-9520113	Sugar Mod Nucleosides
100848.213002AU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	35005	AANA
100848.213002CA	Amino Acid Nucleic Acids	Patent - Foreign	Pending	2202274	AANA
100848.213002CN	Amino Acid Nucleic Acids	Patent - Foreign	Pending	95196989.7 (PCT/US95	AANA
100848.213002CZ	Amino Acid Nucleic Acids	Patent - Foreign	Issued	PV6620/97	AANA
100848.213002E	Amino Acid Nucleic Acids	Patent - Foreign	Pending	95940671.1	AANA
100848.213002HU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	P9702053	AANA
100848.213002JP	Amino Acid Nucleic Acids	Patent - Foreign	Pending	515518/96	AANA
100848.213002KR	Amino Acid Nucleic Acids	Patent - Foreign	Pending	97-702925	AANA
100848.213002MX	Amino Acid Nucleic Acids	Patent - Foreign	Pending	973188	AANA
100848.213002PL	Amino Acid Nucleic Acids	Patent - Foreign	Pending	P320 084	AANA
100848.213002RU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	RU 97108680	AANA
100848.213002SK	Amino Acid Nucleic Acids	Patent - Foreign	Issued	PUV 165-97	AANA
100848.213002UA	Amino Acid Nucleic Acids	Patent - Foreign	Allowed	97041995/M	AANA
100848.213002US3	Amino Acid Nucleic Acids	Patent - US	Issued	08/551947	AANA
100848.213002YU	Amino Acid Nucleic Acids	Patent - Foreign	Issued	P-9520112	AANA
100848.213003AU	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	52958/96	CD28 16064
100848.213003KR	Methods and Compositions for Regulation of CD28 Expression	Patent - Foreign	Issued	97-705496	CD28 16064
100848.213003US2	Methods and Compositions for Regulation of CD28 Expression	Patent - US	Issued	08/529878	CD28 16064
100848.213015AU	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	10531/97	IL8 Antisense
100848.213015RU	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	EA 199800391/26	IL8 Antisense
100848.213015SI	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - Foreign	Issued	P-9620122	IL8 Antisense
100848.213015US2	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - US	Issued	08/796031	IL8 Antisense
100848.213015US4	Inhibition of Tumor Growth by IL-8, IL-8 receptor	Patent - US	Issued	09/055913	IL8 Antisense
100848.213027AU	Control of CD44 Gene Expression for Therapeutic Use	Patent - Foreign	Issued	66866/96	CD44 Antisense
100848.213027US2	Control of CD44 Gene Expression for Therapeutic Use	Patent - US	Issued	08/514542	CD44 Antisense
100848.213028E	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	96944345.6-2110	Glinkosides
100848.213028JP	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Pending	523710/97	Glinkosides

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.213028RU	Carbohydrate Conjugated Bio-active Compounds	Patent - Foreign	Issued	RU 97115878	Glinkosides
100848.213028US1	Carbohydrate Conjugated Bio-active Compounds	Patent - US	Issued	08/576817	Glinkosides
100848.213102AU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	17478/97	Ribavirin
100848.213102BA	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	Up-4270/98	Ribavirin
100848.213102BR	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	PI 9707154-4	Ribavirin
100848.213102CA	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	2246162	Ribavirin
100848.213102CN	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	97191776	Ribavirin
100848.213102CZ	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	PV 2329-98	Ribavirin
100848.213102E	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	97904765.1	Ribavirin
100848.213102E2	Modulation of TH1/TH2 Cytokine Expression by Ribavirin . . .	Patent - Foreign	Pending	1112901.2	Ribavirin
100848.213102E3	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	02009781.2	Ribavirin
100848.213102HK	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	99100284.7	Ribavirin
100848.213102HU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	P9900681	Ribavirin
100848.213102IL	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	125088	Ribavirin
100848.213102JP	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	526907/97	Ribavirin
100848.213102KR	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	PCT/US98/705645	Ribavirin
100848.213102MK	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	P-067/98	Ribavirin
100848.213102MX	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	985963	Ribavirin
100848.213102NO	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	98.3372	Ribavirin
100848.213102NZ	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	330784	Ribavirin
100848.213102PL	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	P.328 003	Ribavirin
100848.213102RU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	RU 98115594/14	Ribavirin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.213102SK	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Pending	PV 1004-98	Ribavirin
100848.213102UA	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Allowed	98073815/M	Ribavirin
100848.213102US1	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	08/603106	Ribavirin
100848.213102US2	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	09/097450	Ribavirin
100848.213102US3	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Issued	09/156646	Ribavirin
100848.213102US4	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Pending	09/624855	Ribavirin
100848.213102US5	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - US	Pending	10/094032	Ribavirin
100848.213102YU	Specific Modulation of TH1/TH2 Cytokine Expression	Patent - Foreign	Issued	P-9720013	Ribavirin
100848.213133US1	Manufacturing L-Ribo-C-nucleosides	Patent - US	Issued	08/603106	Tiazofurin
100848.216009AR	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P99 01 01930	Purine-L-Nucleosides
100848.216009AR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P 01 01 01046	Purine-L-Nucleosides
100848.216009AU	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	48999/97	Purine-L-Nucleosides
100848.216009AU2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	45137/00	Purine-L-Nucleosides
100848.216009BA	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	BAP99418A	Purine-L-Nucleosides
100848.216009BA	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	BAP-00613A	Purine-L-Nucleosides
100848.216009BR	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PI 9714349-9	Purine-L-Nucleosides
100848.216009BR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending		Purine-L-Nucleosides
100848.216009CA	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2323791	Purine-L-Nucleosides
100848.216009CA2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2266889	Purine-L-Nucleosides
100848.216009CN2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	00122459.X	Purine-L-Nucleosides
100848.216009CN3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	00122458.1	Purine-L-Nucleosides
100848.216009CZ2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 1999-1267	Purine-L-Nucleosides
100848.216009CZ3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 2000-2532	Purine-L-Nucleosides
100848.216009E	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	97911684.5	Purine-L-Nucleosides
100848.216009E(2)	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	00118428.2110	Purine-L-Nucleosides
100848.216009HK	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	100589.7	Purine-L-Nucleosides
100848.216009HK2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	01103600.5	Purine-L-Nucleosides
100848.216009HR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	P20000420A	Purine-L-Nucleosides
100848.216009HR3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	P20000422A	Purine-L-Nucleosides
100848.216009HU	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P0001186	Purine-L-Nucleosides
100848.216009HU2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P00 02452	Purine-L-Nucleosides
100848.216009IL2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	137390	Purine-L-Nucleosides
100848.216009IL3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	137391	Purine-L-Nucleosides
100848.216009IN	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	335/Cal/99	Purine-L-Nucleosides

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216009JP	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	518475/98	Purine-L-Nucleosides
100848.216009JP2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2001-110027	Purine-L-Nucleosides
100848.216009KR	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1999-7003276	Purine-L-Nucleosides
100848.216009KR2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	(PCT) 2000-7014248	Purine-L-Nucleosides
100848.216009MK	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-30/99	Purine-L-Nucleosides
100848.216009MK2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-20000060	Purine-L-Nucleosides
100848.216009MX	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	993285	Purine-L-Nucleosides
100848.216009MX2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	009526	Purine-L-Nucleosides
100848.216009NO2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000 4326	Purine-L-Nucleosides
100848.216009NO3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000 4328	Purine-L-Nucleosides
100848.216009NZ2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	505554	Purine-L-Nucleosides
100848.216009NZ3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	505553	Purine-L-Nucleosides
100848.216009PL	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P.332694	Purine-L-Nucleosides
100848.216009RU	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	RU 99109467	Purine-L-Nucleosides
100848.216009RU2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	RU-2000122129	Purine-L-Nucleosides
100848.216009SB	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-188/99	Purine-L-Nucleosides
100848.216009SB2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-435/2000	Purine-L-Nucleosides
100848.216009SI	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	P-9720067	Purine-L-Nucleosides
100848.216009SK	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 481-99	Purine-L-Nucleosides
100848.216009SK2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 1158-2000	Purine-L-Nucleosides
100848.216009UA2	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000073982/I	Purine-L-Nucleosides
100848.216009UA3	Purine-L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2000073983/I	Purine-L-Nucleosides
100848.216009US3	Purine L-Nucleosides (DIV-narrow)	Patent - US	Allowed	09/594271	Purine-L-Nucleosides
100848.216009US4	Purine L-Nucleosides (DIV-broad)	Patent - US	Pending	09/595364	Purine-L-Nucleosides
100848.216009US5	Purine L-Nucleosides (DIV-narrow)	Patent - US	Pending	10/058855	Purine-L-Nucleosides
100848.216010AR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	11324	Levovirin 17261
100848.216010AU	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	49867/97	Levovirin 17261
100848.216010BA	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	Up-2178/99	Levovirin 17261
100848.216010BR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PI 9712527-0	Levovirin 17261
100848.216010CA	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2267279	Levovirin 17261
100848.216010CN	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	97180619.5	Levovirin 17261
100848.216010CZ	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 1206-99	Levovirin 17261
100848.216010E	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	97912762.8	Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216010E2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1108303.7	Levovirin 17261
100848.216010E3	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	2007191.6	Levovirin 17261
100848.216010HK	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	106873.9	Levovirin 17261
100848.216010HK2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1107955.7	Levovirin 17261
100848.216010HR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	P990147A	Levovirin 17261
100848.216010HU	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P0001107	Levovirin 17261
100848.216010IL	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	129126	Levovirin 17261
100848.216010IN	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	336/Cal/99	Levovirin 17261
100848.216010JP	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	518612/98	Levovirin 17261
100848.216010KR	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	(PCT) 1999-7003326	Levovirin 17261
100848.216010MK	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-31/99	Levovirin 17261
100848.216010MX	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	993434	Levovirin 17261
100848.216010NO	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	1999 1785	Levovirin 17261
100848.216010NZ	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	334915	Levovirin 17261
100848.216010PL	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P.333419	Levovirin 17261
100848.216010RU	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Allowed	RU 99109459	Levovirin 17261
100848.216010RU2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	RU 2001132536	Levovirin 17261
100848.216010SB	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	P-187/99	Levovirin 17261
100848.216010SI	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Issued	P-9720065	Levovirin 17261
100848.216010SK	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	PV 471-99	Levovirin 17261
100848.216010UA	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - Foreign	Pending	99042175	Levovirin 17261

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216010US1	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Issued	09/291903	Levovirin 17261
100848.216010US2	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Allowed	09/633493	Levovirin 17261
100848.216010US3	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending	09/969355	Levovirin 17261
100848.216010US4	Monocyclic L-Nucleosides, Analogs and Uses Thereof	Patent - US	Pending	10/120101	Levovirin 17261
100848.216011AR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	1501149	Tiazofurin
100848.216011AU	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Issued	82688/98	Tiazofurin
100848.216011BA	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	BAP99523A	Tiazofurin
100848.216011BR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PI 9810364-4	Tiazofurin
100848.216011CA	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	2290364	Tiazofurin
100848.216011CN	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	98806383.2	Tiazofurin
100848.216011CZ	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PV 4631-99	Tiazofurin
100848.216011E	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	98932904	Tiazofurin
100848.216011HR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P990365A	Tiazofurin
100848.216011HU	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P0002389	Tiazofurin
100848.216011IL	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	132737	Tiazofurin
100848.216011JP	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	505797/99	Tiazofurin
100848.216011KR	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PCT/US701255	Tiazofurin
100848.216011MK	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P-100/99	Tiazofurin
100848.216011MX	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	9911409	Tiazofurin
100848.216011NO	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	1999 6467	Tiazofurin
100848.216011NZ	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Issued	500831	Tiazofurin

ICN Files Transferred to Ribapharm

Rutan Matter ID	Title	MatterType	Status	Serial Number	Ribapharm Client Ref.
100848.216011PL	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P.337716	Tiazofurin
100848.216011RU	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	RU 2000100307	Tiazofurin
100848.216011SB	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	P-670/99	Tiazofurin
100848.216011SI	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Issued	P-9820052	Tiazofurin
100848.216011SK	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	PV 1723-99	Tiazofurin
100848.216011UA	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - Foreign	Pending	99126884	Tiazofurin
100848.216011US1	Method of Producing Tiazofurin and Other C-Nucleosides	Patent - US	Pending	09/445713	Tiazofurin
100848.216012AU	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	62367/98	Pyridostigmine
100848.216012NZ	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	335419	Pyridostigmine
100848.216012SI	Multi-Valent Salts of Pyridostigmine	Patent - Foreign	Issued	P9720075	Pyridostigmine
100848.216012US1	Multi-Valent Salts of Pyridostigmine	Patent - US	Issued	09/308723	Pyridostigmine
100848.216013E	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending	97953460.9	G-rich Oligo Aptamers
100848.216013JP	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Pending	530233/98	G-rich Oligo Aptamers
100848.216013SI	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - Foreign	Issued	P-9720081	G-rich Oligo Aptamers
100848.216013US1	G-rich Oligo Aptamers and Methods of Modulating an Immune Response	Patent - US	Pending	09/331204	G-rich Oligo Aptamers